Lutetium Lu 177 Zadavotide Guraxetan

**Semantic type:** Pharmacologic Substance

**Definition:** A radioconjugate composed of zadavotide guraxetan, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity. Upon administration of lutetium Lu-177 zadavotide guraxetan, the zadavotide guraxetan moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.

**Synonyms:** - 177Lu-PNT2002 - 177Lu-labeled PNT2002 - 177Lu-labeled PSMA I&T - LUTETIUM LU-177 ZADAVOTIDE GURAXETAN - Lu-177-PSMA-I&T - Lu177-PNT2002 - Lutetium Lu 177 PSMA I&T - Lutetium Lu 177-PSMA-I&T - Lutetium Lu-177 PNT2002 - Lutetium Lu-177-PNT2002 - Zadavotide Guraxetan Lutetium Lu-177 - [Lu-177]-PNT2002 - [Lu-177]-PSMA-I and T